Latest news with #AmulyaNidhi
Time of India
9 hours ago
- Health
- Time of India
MP's maternal mortality ratio drops to 159 but calls for urgent reflection
Bhopal: The Special Bulletin on Maternal Mortality in India 2020-22 reveals that Madhya Pradesh's MMR has decreased to 159 from 173 (2019-21). Despite this progress, the state continues to have concerning maternal health statistics. At 159, Madhya Pradesh records the highest MMR amongst all states, considerably exceeding the national figure of 88. Report indicates need to address deficiencies in maternal healthcare delivery, including insufficient prenatal care services, institutional birth facilities and emergency obstetric care. The state reports a maternal mortality rate of 14, alongside a 0.47 per cent lifetime risk of maternal death, which ranks highest across Indian states, as per SRS data. These statistics underscore the serious health risks faced by expectant mothers in the region. Jan Swasthya Abhiyan India (JSAI) representative Amulya Nidhi attributes these concerns to fundamental issues including insufficient healthcare infrastructure, uneven distribution of rural health services, and social and economic barriers affecting maternal health. He emphasised the necessity for transparent maternal death audit. Considering the significantly lower MMR in other states, Madhya Pradesh needs immediate strategic interventions to enhance maternal health programmes, boost public awareness, and ensure healthcare accessibility and affordability. According to Nidhi, these measures are essential to enhance survival rates and reduce avoidable maternal fatalities.
Time of India
15 hours ago
- Health
- Time of India
MP's maternal mortality ratio drops to 159 but calls for urgent reflection
Bhopal: The Special Bulletin on Maternal Mortality in India 2020-22 reveals that Madhya Pradesh's MMR has decreased to 159 from 173 (2019-21). Despite this progress, the state continues to have concerning maternal health statistics. At 159, Madhya Pradesh records the highest MMR amongst all states, considerably exceeding the national figure of 88. Report indicates need to address deficiencies in maternal healthcare delivery, including insufficient prenatal care services, institutional birth facilities and emergency obstetric care. The state reports a maternal mortality rate of 14, alongside a 0.47% lifetime risk of maternal death, which ranks highest across Indian states, as per SRS data. These statistics underscore the serious health risks faced by expectant mothers in the region. Jan Swasthya Abhiyan India (JSAI) representative Amulya Nidhi attributes these concerns to fundamental issues including insufficient healthcare infrastructure, uneven distribution of rural health services, and social and economic barriers affecting maternal health. He emphasised the necessity for transparent maternal death audit. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với mức chênh lệch giá thấp nhất IC Markets Đăng ký Undo Considering the significantly lower MMR in other states, Madhya Pradesh needs immediate strategic interventions to enhance maternal health programmes, boost public awareness, and ensure healthcare accessibility and affordability. According to Nidhi, these measures are essential to enhance survival rates and reduce avoidable maternal fatalities.
Time of India
24-04-2025
- Health
- Time of India
Oversights raise health safety concerns: Experts
Ahmedabad: The civic body investigating committee's decision to ignore clinical trial subjects, particularly those who come into public hospitals for treatment, raises the serious issue of public health safety, experts say. "Ignoring subjects in the whole investigations means you have exposed vulnerable people to risk because established norms and due process are not being followed at your hospital," observes Amulya Nidhi of Swasthya Adhikar Manch, who is a petitioner in the writ petition civil case No 33 of 2012 in the Supreme Court concerning clinical trials. According to the latest New Drugs and Clinical Trials Rules, 2019, an ethics committee (EC) at a clinical trial site is compulsory and should be appointed by the institutional head, not by the sponsor of the trial. When the Ahmedabad Municipal Corporation (AMC) committee investigating the issue examined clinical trials approved between 2022 and 2024 at VS Hospital and registered with the Clinical Trial Registry, India, a list of new approvals for a range of trials were noticed. These included Phase 3 and Phase 4 trials that cover vaccines for measles, rubella, typhoid and yellow fever, a drug for moderate to severe psoriasis, a treatment for Parkinson's disease, a drug for Type 2 diabetes, and a herbal formulation for mild Covid-19. A senior AMC official told TOI, "If the internal committee doesn't have the capacity to investigate due process, their options are to constitute an independent committee of experts or write to the central authority (like the DCGI or the secretary, ministry of health) to probe the entire issue." Nidhi argues, "If non-financial violations are found during the investigation, the committee must also look into them; focusing only on financial transactions is insufficient."
